Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment
Abstract Background New disease-modifying ways to treat Parkinson’s disease (PD) may soon become a reality with intracerebral transplantation of cell products produced from human embryonic stem cells (hESCs). The aim of this study was to assess what factors influence preferences of patients with PD...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | BMC Medical Ethics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12910-023-00966-1 |
| _version_ | 1797556673450082304 |
|---|---|
| author | Karin Schölin Bywall Jennifer Drevin Catharina Groothuis-Oudshoorn Jorien Veldwijk Dag Nyholm Hakan Widner Trinette van Vliet Elena Jiltsova Mats Hansson Jennifer Viberg Johansson |
| author_facet | Karin Schölin Bywall Jennifer Drevin Catharina Groothuis-Oudshoorn Jorien Veldwijk Dag Nyholm Hakan Widner Trinette van Vliet Elena Jiltsova Mats Hansson Jennifer Viberg Johansson |
| author_sort | Karin Schölin Bywall |
| collection | DOAJ |
| description | Abstract Background New disease-modifying ways to treat Parkinson’s disease (PD) may soon become a reality with intracerebral transplantation of cell products produced from human embryonic stem cells (hESCs). The aim of this study was to assess what factors influence preferences of patients with PD regarding stem-cell based therapies to treat PD in the future. Methods Patients with PD were invited to complete a web-based discrete choice experiment to assess the importance of the following attributes: (i) type of treatment, (ii) aim of treatment, (iii) available knowledge of the different types of treatments, (iv) effect on symptoms, and (v) risk for severe side effects. Latent class conditional logistic regression models were used to determine preference estimates and heterogeneity in respondents’ preferences. Results A substantial difference in respondents’ preferences was observed in three latent preference patterns (classes). “Effect on symptoms” was the most important attribute in class 1, closely followed by “type of treatment,” with medications as preferred to other treatment alternatives. Effect on symptoms was also the most important attribute in class 2, with treatment with hESCs preferred over other treatment alternatives. Likewise for class 3, that mainly focused on “type of treatment” in the decision-making. Respondents’ class membership was influenced by their experience in treatment, side effects, and advanced treatment therapy as well as religious beliefs. Conclusions Most of the respondents would accept a treatment with products emanating from hESCs, regardless of views on the moral status of embryos. Preferences of patients with PD may provide guidance in clinical decision-making regarding treatments deriving from stem cells. |
| first_indexed | 2024-03-10T17:05:13Z |
| format | Article |
| id | doaj.art-bc84992b6fcd4003b7f8cfc427ae8b8f |
| institution | Directory Open Access Journal |
| issn | 1472-6939 |
| language | English |
| last_indexed | 2024-03-10T17:05:13Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medical Ethics |
| spelling | doaj.art-bc84992b6fcd4003b7f8cfc427ae8b8f2023-11-20T10:50:15ZengBMCBMC Medical Ethics1472-69392023-10-0124111310.1186/s12910-023-00966-1Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experimentKarin Schölin Bywall0Jennifer Drevin1Catharina Groothuis-Oudshoorn2Jorien Veldwijk3Dag Nyholm4Hakan Widner5Trinette van Vliet6Elena Jiltsova7Mats Hansson8Jennifer Viberg Johansson9School of Health, Care and Social Welfare, Division of Health and Welfare Technology, Mälardalen UniversityCentre for Research Ethics and Bioethics, Uppsala UniversityHealth Technology and Services Research (HTSR), Faculty of Behavioural Management and Social Sciences, University of TwenteCentre for Research Ethics and Bioethics, Uppsala UniversityDepartment of Medical Sciences, Uppsala University, Uppsala University HospitalDepartment of Neurology, Skåne University HospitalDepartment of Neurology, Skåne University HospitalDepartment of Medical Sciences, Uppsala University, Uppsala University HospitalCentre for Research Ethics and Bioethics, Uppsala UniversityCentre for Research Ethics and Bioethics, Uppsala UniversityAbstract Background New disease-modifying ways to treat Parkinson’s disease (PD) may soon become a reality with intracerebral transplantation of cell products produced from human embryonic stem cells (hESCs). The aim of this study was to assess what factors influence preferences of patients with PD regarding stem-cell based therapies to treat PD in the future. Methods Patients with PD were invited to complete a web-based discrete choice experiment to assess the importance of the following attributes: (i) type of treatment, (ii) aim of treatment, (iii) available knowledge of the different types of treatments, (iv) effect on symptoms, and (v) risk for severe side effects. Latent class conditional logistic regression models were used to determine preference estimates and heterogeneity in respondents’ preferences. Results A substantial difference in respondents’ preferences was observed in three latent preference patterns (classes). “Effect on symptoms” was the most important attribute in class 1, closely followed by “type of treatment,” with medications as preferred to other treatment alternatives. Effect on symptoms was also the most important attribute in class 2, with treatment with hESCs preferred over other treatment alternatives. Likewise for class 3, that mainly focused on “type of treatment” in the decision-making. Respondents’ class membership was influenced by their experience in treatment, side effects, and advanced treatment therapy as well as religious beliefs. Conclusions Most of the respondents would accept a treatment with products emanating from hESCs, regardless of views on the moral status of embryos. Preferences of patients with PD may provide guidance in clinical decision-making regarding treatments deriving from stem cells.https://doi.org/10.1186/s12910-023-00966-1EthicsHuman embryonic stem cellsParkinson’s diseasePatient preferences |
| spellingShingle | Karin Schölin Bywall Jennifer Drevin Catharina Groothuis-Oudshoorn Jorien Veldwijk Dag Nyholm Hakan Widner Trinette van Vliet Elena Jiltsova Mats Hansson Jennifer Viberg Johansson Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment BMC Medical Ethics Ethics Human embryonic stem cells Parkinson’s disease Patient preferences |
| title | Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment |
| title_full | Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment |
| title_fullStr | Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment |
| title_full_unstemmed | Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment |
| title_short | Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment |
| title_sort | patients accept therapy using embryonic stem cells for parkinson s disease a discrete choice experiment |
| topic | Ethics Human embryonic stem cells Parkinson’s disease Patient preferences |
| url | https://doi.org/10.1186/s12910-023-00966-1 |
| work_keys_str_mv | AT karinscholinbywall patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT jenniferdrevin patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT catharinagroothuisoudshoorn patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT jorienveldwijk patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT dagnyholm patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT hakanwidner patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT trinettevanvliet patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT elenajiltsova patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT matshansson patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment AT jennifervibergjohansson patientsaccepttherapyusingembryonicstemcellsforparkinsonsdiseaseadiscretechoiceexperiment |